Cargando…

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants

Asciminib, a first‐in‐class BCR‐ABL1 inhibitor that works by Specifically Targeting the ABL Myristoyl Pocket (STAMP), is a new treatment option for patients with chronic myeloid leukemia who no longer benefit from currently approved tyrosine kinase inhibitors. In vitro, asciminib reversibly inhibits...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoch, Matthias, Sengupta, Tirtha, Hourcade‐Potelleret, Florence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199882/ https://www.ncbi.nlm.nih.gov/pubmed/35293131 http://dx.doi.org/10.1111/cts.13252

Ejemplares similares

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents
por: Hoch, Matthias, et al.
Publicado: (2022)

Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2019)

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)

Probing Steroidal Substrate Specificity of Cytochrome P450 BM3 Variants
por: Liu, Xing, et al.
Publicado: (2016)

Evaluation of Luminogenic Substrates as Probe Substrates for Bacterial Cytochrome P450 Enzymes: Application to Mycobacterium tuberculosis
por: Ortega Ugalde, Sandra, et al.
Publicado: (2019)

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450
por: Campelo, Diana, et al.
Publicado: (2018)

Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate
por: van Dyk, Madelé, et al.
Publicado: (2019)

Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed-Dose Subcutaneous Formulation of Trastuzumab
por: Hourcade-Potelleret, F, et al.
Publicado: (2014)

1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology
por: de Montellano, Paul R Ortiz
Publicado: (2018)

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein
por: Cho, Hyun-Jong, et al.
Publicado: (2015)

Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin
por: Sumsakul, Wiriyaporn, et al.
Publicado: (2016)

Asciminib for chronic myeloid leukaemia
Publicado: (2022)

Homotropic Cooperativity of Midazolam Metabolism by Cytochrome P450 3A4: Insight from Computational Studies
por: Li, Junhao, et al.
Publicado: (2021)

Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study
por: Ermer, James, et al.
Publicado: (2015)

Development of Novel S-Protective Thiolated-Based Mucoadhesive Tablets for Repaglinide: Pharmacokinetic Study
por: Alhakamy, Nabil A., et al.
Publicado: (2022)

Substrate binding induces structural changes in cytochrome P450cam
por: Sakurai, Keisuke, et al.
Publicado: (2009)

Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam
por: Togao, Masao, et al.
Publicado: (2020)

Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
por: Lammers, Laureen A., et al.
Publicado: (2017)

Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects
por: Greene, Stephen A., et al.
Publicado: (2021)

Dissecting the Cytochrome P450 OleP Substrate Specificity: Evidence for a Preferential Substrate
por: Parisi, Giacomo, et al.
Publicado: (2020)

Simultaneous Determination of Five Cytochrome P450 Probe Substrates and Their Metabolites and Organic Anion Transporting Polypeptide Probe Substrate in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry
por: Heo, Jae-Kyung, et al.
Publicado: (2018)

Repaglinide-Induced Acute Pancreatitis
por: Udongwo, Ndausung, et al.
Publicado: (2021)

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole
por: Patel, Chirag G, et al.
Publicado: (2011)

Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs
por: Sun, Hao, et al.
Publicado: (2018)

Green analytical method for the simultaneous analysis of cytochrome P450 probe substrates by poly(N-isopropylacrylamide)-based temperature-responsive chromatography
por: Maekawa, Yutaro, et al.
Publicado: (2020)

Insights into the Role of Substrates on the Interaction between Cytochrome b(5) and Cytochrome P450 2B4 by NMR
por: Zhang, Meng, et al.
Publicado: (2015)

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
por: Han, Ji Min, et al.
Publicado: (2020)

Formulation and Evaluation of Transdermal Patch of Repaglinide
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
por: Armani, Sara, et al.
Publicado: (2017)

Strength of Axial Water Ligation in Substrate-Free Cytochrome P450s Is Isoform Dependent
por: Conner, Kip P., et al.
Publicado: (2014)

Structural Insights into the Mechanism for Recognizing Substrate of the Cytochrome P450 Enzyme TxtE
por: Yu, Feng, et al.
Publicado: (2013)

Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding
por: Esteves, Francisco, et al.
Publicado: (2020)

An integrated screening system for the selection of exemplary substrates for natural and engineered cytochrome P450s
por: Kanoh, Naoki, et al.
Publicado: (2019)

Molecular determinant of substrate binding and specificity of cytochrome P450 2J2
por: Xu, Liang, et al.
Publicado: (2020)

The Cytochrome P450 Homepage
por: Nelson, David R
Publicado: (2009)

The Development and Validation of a Novel “Dual Cocktail” Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions
por: Kwon, Mihwa, et al.
Publicado: (2020)

CYPstrate: A Set of Machine Learning Models for the Accurate Classification of Cytochrome P450 Enzyme Substrates and Non-Substrates
por: Holmer, Malte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cnq19tpgau7u3p46a6s0q2esa9